3189 results for «750»
3189 results
Heart Team in action: managing complex cases together
17 Feb 2024 – From PCR Tokyo Valves 2024
In this group discussion, several heart teams present their work on complex cases of tricuspid valve interventions and explore the results of their collaboration in order to figure out adequate management for invasive treatments.
Rapid-fire - Complex procedure in TAVI - Part 2
18 Feb 2024 – From PCR Tokyo Valves 2024
In the second part of this rapid-fire session, we continue to focus on complex cases that might arise during TAVI, such as a case of prosthetic aortic valve endocarditis resulting in cardiogenic shock, treatment of severe AR after infective endocarditis, and more!
Rapid-fire - Complications of Mitral TEER - Part 2
18 Feb 2024 – From PCR Tokyo Valves 2024
Gain valuable insights into the possible complications of Mitral Transcatheter Edge-to-Edge Repair (TEER) in the second part of this session rapid-fire submission cases [in Japanese].
Nightmares in TAVI: sharing solutions together
18 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session to learn more about bailout techniques for TAVI during uncommon complications, such as late coronary obstruction post-TAVI, a migrated self-expandable valve, or a C-tab induced iatrogenic thoracic aortic dissection after Evolut FX implantation.
Imaging for aortic valve disease
18 Feb 2024 – From PCR Tokyo Valves 2024
Learn about imaging of the aortic valve system in order to better deal with aortic valve disease. Through this series of cases, explore topics such as the impact of implantation depth relative to membranous septum on TAVI outcomes, delve into a meta-analysis exploring the outcomes of...
Pi-Cardia’s ShortCut™ Becomes First Leaflet Modification Technology to Receive CMS NTAP for Valve-in-Valve TAVR
06 Aug 2025
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Meril Life Sciences presents one-year outcomes from the LANDMARK randomized controlled trial at PCR London Valves 2025
16 Nov 2025
In Person in Paris and online EuroPCR 2022 celebrates the best of both worlds
09 May 2022
EuroPCR is celebrating being back home in Paris, in-person, for the first time in 3 years. This year’s international Course will see both a complete on-site programme and a full digital experience, bringing the community together to share and learn.
